Corporate Presentation J.B.Chemicals & Pharmaceuticals Ltd. www.jbcpl.com

Forward Looking Statements In this presentation we have disclosed forward looking information to enable investors to comprehend our prospects and take informed investment decisions. This presentation and other statements, written and oral, that we periodically make contain forward looking statements that set out anticipated results based on the management’s plan and assumptions. We have tried wherever possible to identify such statements by using words such as ‘anticipate’, ‘aims’ ‘estimate’, ‘expects’, ‘project’, ‘intends’, ‘plans’, ‘believes’, and words of similar substance in connection with any discussion of future performance. We cannot guarantee that these forward looking statements will be realized, although we believe we have been prudent in assumptions. The achievement of results is subject to risks, uncertainties and even inaccurate assumptions. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. Everybody should bear this in mind.

COMPANY BUSINESS UNITS MANUFACTURING STRATEGY

Background The name J. B. Chemicals & Pharmaceuticals Ltd. was christened after Mr. J. B. Mody who is the Chairman and founder of JBCPL JBCPL is a leading and publicly traded pharmaceutical company in India Leading by the vision and dynamism of Mr. J. B. Mody, a visionary and pioneer with an experience of over five decades in the pharmaceutical industry, the group has diversified into different sectors

Brief on JBCPL Incorporated in 1976 with an IPO in 1985 Listed on the BSE and NSE with a market cap of USD 110 million Manufacturing facilities in Gujarat and Maharashtra for formulations and API Subsidiary in South Africa and Russia Total employee strength of 2900

2012-13 Quarterly Revenues & Profits Rs. in crores Financial year: April 2012 – March 2013

2012-13 Quarterly Revenues & Profits USD in millions Financial year: April 2012 – March 2013

Annual Revenues & Profits Rs. in crores * Divestment of Russia-CIS OTC business to J&J

Annual Revenues & Profits USD in millions * Divestment of Russia-CIS OTC business to J&J

Strategic Business Units INDIA Prescription and Hospital CONTRAST MEDIA GLOBAL ANDA Contract Manufacturing Branded Generics OTC Contrast Media API RUSSIA & CIS OTC, Prescription, Hospital JBCPL INDIA 40% CONTRAST MEDIA 5% GLOBAL 30% API 7% RUSSIA & CIS 18% BUSINESS DEVELOPMENT

India Prescription products Domestic market estimated at about USD 11 billion and growing by about 18% as per ORG JBCPL Ranked 35th (ORG) with 3 brands featuring in top 300 brands reported by ORG JBCPL continued consolidation process during 2011-12, and adopted key brands focus marketing strategy Top 4 therapeutic segments: Gastro-enterology, Cardiovascular, Pain management and Antibiotic Acute segment contributes about 82% of total sales Current field force: 1100 sales representatives

India Growth Plan JBCPL has placed increased concentration on domestic market for next level growth. Increase in field force New product introductions JBCPL plans to increase field force to 1500 in 2012-13. This is aimed at strengthening rural market presence with strength increase in urban market too

Contrast Media – niche focus Contrast Media Products Caters to niche radio-diagnostic products used in CT Scan, MRI and Cath Lab through 30 sales representatives Iopamidol Iohexol Gadopentetate dimeglumine Diatrizoate Meglumine In-licensed a new Ultrasound Contrast Imagining product (Definity) of Lantheus Medical Imaging Inc. from USA

Russia/Ukraine/CIS Latvia Estonia Lithuania Byelorussia Ukraine Maldova Russia Georgia Armenia Kazakhstan Azerbaijan Turkmenistan Uzbekistan Mongolia Kyrghyztan Tajikistan

Russia/Ukraine/CIS Russian market is estimated to be about US $12 billion at retail level, growing by about 7% in value annually JBCPL is ranked amongst the top Indian companies Entered Russia in 1992 Offices in Russia/Ukraine and some CIS countries

Russia/Ukraine/CIS Divested OTC portfolio to Johnson & Johnson in May 2011 Contract manufacturing for J&J for these OTC products Prescription business continues through wholly owned subsidiary in Russia

Global Contract Manufacturing and Product pipeline will increase to fuel growth Activity wise breakup

Global Top markets breakup

South Africa In 2007, JBCPL has made strategic investment in Biotech Laboratories (Pty) Ltd., South Africa, a BEE marketing and sales, marketing and distribution company Have 49% equity stake with preference shares to take it to 51% Robust products pipeline to strengthen direct business with Biotech

Contract Manufacturing Contract Manufacturing (Clear Focus) Projects awarded by multinationals globally More than 10 clients Tailor made services for customers Injectables Vials Ampoules Form Fill Sealed Semi-solid Creams Ointments Gels Solid Tablets Lozenges Herbal Medicated

Contract Manufacturing Complete package New Product development Analytics services Technology transfer Regulatory support Manufacturing

Lozenges Lozenges, a JBCPL niche strength, has excellent scope in global market Medicated and Herbal We manufacture lozenges under our own brands and private label Private label lozenges for leading UK/EU, South African, Australian and Canadian companies.

API Business JBCPL manufactures 2 APIs one of the largest manufacturer of Diclofenac Sodium (BP, EP, USP) and Nifedipine

Brands | Assets Zecuf herbal Cough and Cold Nicardia (Nifedipine) Anti-hypertensive Metrogyl (Metronidazole) Anaerobicide Rantac (Ranitidine) Anti-peptic ulcerant Panum (Pantaprazole) OF (Ofloxacin) Antibiotic Dicloran (Diclofenac Sodium) NSAID

Manufacturing Facilities At Daman Located at Kadaiya, Daman Manufactures lozenges and tablets Lozenges approved by: UK MHRA TGA Australia MCC South Africa FDB Ghana

Manufacturing Facilities At Gujarat Plant TI – 10 Located at Panoli Manufactures tablets Facility approved by US FDA UK MHRA TGA Australia MCC South Africa INVIMA Colombia Germany (EU-GMP)

Manufacturing Facilities At Gujarat Plant IV -17 Located at Panoli Manufactures injectables - FFS, vials and ampoules Facility approved by: MCC South Africa INVIMA Colombia

Manufacturing Facilities At Gujarat Plant IV -14 Located at Panoli Manufactures injectables, ointments & cold rubs Facility approved by: MCC South Africa NDA Uganda Pharmacy Board Tanzania INVIMA Colombia

Manufacturing Facilities At Gujarat Plant L-6 Located at Panoli Manufactures herbal liquids

Manufacturing Facilities At Gujarat Plant D 9 Located at Panoli Manufactures Diclofenac API Facility approved by: US FDA Germany EU-GMP

Manufacturing Facilities At Gujarat Plant UM 12 Located at Ankleshwar Manufactures tablets and liquids Facility approved by: NDA - Uganda (Tablets & liquids) Pharmacy Board - Tanzania (liquid)

Strategy ANDA: Develop and manufacture products for USA market Contract Manufacturing: Increase our customer base by providing quality products at cost effective prices Russia marketing: Form JV/Partnerships for marketing New Territories: Expand into newer territories through partnerships Capacities: Enhance capacities in 2012-13 for ANDA and contract manufacturing tablets Injectables Lozenges

Thank You J.B.Chemicals & Pharmaceuticals Ltd. +91-22-30451200 | corporate@jbcpl.com www.jbcpl.com J.B.Chemicals & Pharmaceuticals Ltd.